Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PSTV Plus Therapeutics, Inc.

Trading 03-28 12:13:08 EDT

1.20

-0.32

-21.05%

High1.36	Low1.15	Vol2.42M
Open1.30	D1 Closing1.52	Amplitude13.80%
Mkt Cap7.08M	Tradable Cap6.90M	Total Shares5.90M
T/O2.96M	T/O Rate42.12%	Tradable Shares5.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"PSTV","market":"US","secType":"STK","nameCN":"Plus Therapeutics, Inc.","latestPrice":1.2,"timestamp":1743178382809,"preClose":1.52,"halted":0,"volume":2420401,"delay":0,"floatShares":5746200,"shares":5896300,"eps":-3.090557,"marketStatus":"Trading","change":-0.32,"latestTime":"03-28 12:13:08 EDT","open":1.3,"high":1.3597,"low":1.15,"amount":2961881.009715,"amplitude":0.137961,"askPrice":1.2,"askSize":300,"bidPrice":1.19,"bidSize":17,"shortable":0,"etf":0,"ttmEps":-3.090557,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743192000000},"marketStatusCode":2,"adr":0,"listingDate":1134968400000,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.36,"preClose":1.52,"latestTime":"09:29 EDT","volume":155515,"amount":214178.026167,"timestamp":1743168569131},"postHourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.52,"latestTime":"19:59 EDT","volume":1943820,"amount":2544958.1049,"timestamp":1743119988174},"volumeRatio":0.317302},"requestUrl":"/m/hq/s/PSTV","defaultTab":"news","newsList":[{"id":"2522520412","title":"Plus Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520412","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520412?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:35","pubTimestamp":1743161700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PSTV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 28, 2025 07:35 ET (11:35 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","PSTV"],"gpt_icon":0},{"id":"2522192765","title":"Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2522192765","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522192765?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 15:04","pubTimestamp":1743145487,"startTime":"0","endTime":"0","summary":"Cash and Investments Balance: $3.6 million as of December 31, 2024, compared to $8.6 million at December 31, 2023.Grant Revenue: $5.8 million in 2024, up from $4.9 million in 2023.Operating Loss: $14.7 million in 2024, compared to $13.3 million in 2023.Net Loss: $13 million or $0.95 per share in 2024, compared to $13.3 million or $4.24 per share in 2023.Equity Financing: $15 million in gross proceeds from an underwritten equity financing in early March 2025.Grant Funding for 2025: Expected to be in the range of $6 to $8 million.Additional Grant Proceeds: $7.2 million remaining to be received from grants, with $2 million received in Q1 2025.Department of Defense Grant: Over $2 million remaining from a $3 million award for the Respect pediatric brain cancer trial.GuruFocus has detected 1 Warning Sign with PSTV.Plus Therapeutics Inc  successfully completed an underwritten equity financing of $15 million, strengthening its balance sheet and funding key milestones into mid-2026.Plus Therape","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plus-therapeutics-inc-pstv-q4-070447595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSTV"],"gpt_icon":1},{"id":"2522551869","title":"Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522551869","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522551869?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 05:35","pubTimestamp":1743111303,"startTime":"0","endTime":"0","summary":"Plus Therapeutics  came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items.Plus , which belongs to the Zacks Medical - Drugs industry, posted revenues of $1.41 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 6.49%. This compares to year-ago revenues of $1.31 million. The company has topped consensus revenue estimates just once over the last four quarters.Plus shares have added about 27.8% since the beginning of the year versus the S&P 500's decline of -2.9%.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-rank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plus-therapeutics-pstv-reports-q4-213503665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSTV"],"gpt_icon":1},{"id":"2522130532","title":"Plus Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522130532","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522130532?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 05:01","pubTimestamp":1743109260,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryPlus Therapeutics Inc PSTV.OQ reported a quarterly adjusted loss of 49 cents per share for the quarter ended D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA25G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV"],"gpt_icon":1},{"id":"2522876531","title":"Plus Therapeutics FY24 EPS $(1.95) Vs. $(4.24) YoY, Grant Revenue $5.8M Up From $4.9M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2522876531","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522876531?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:16","pubTimestamp":1743106574,"startTime":"0","endTime":"0","summary":"Plus Therapeutics FY24 EPS $(1.95) Vs. $(4.24) YoY, Grant Revenue $5.8M Up From $4.9M YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44524130/plus-therapeutics-fy24-eps-1-95-vs-4-24-yoy-grant-revenue-5-8m-up-from-4-9m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","LENZ"],"gpt_icon":0},{"id":"2522391655","title":"BRIEF-Plus Therapeutics FY Net Income USD -12.978 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522391655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522391655?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105946,"startTime":"0","endTime":"0","summary":"BRIEF-Plus Therapeutics FY Net Income USD -12.978 Million\n\n\nMar 27 (Reuters) - Plus Therapeutics FY operating income USD -14.695 million.\n\nFY operating expenses USD 20.519 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXBBDF57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2522396425","title":"Plus Therapeutics FY Operating Expenses USD 20.519 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522396425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522396425?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXBBDF57:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2522470531","title":"Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522470531","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522470531?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"The recent $15 million financing accelerates development of REYOBIQ and launch of CNSide. HOUSTON, March 27, 2025  -- Plus Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system  cancers, today announcesfinancial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights.“Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “The recently raised capital, coupled with existing grant support, enables us to progress both our therapeutic programs to key clinical and regulatory milestones as well as commercially launch our CNSide diagnostic platform. The year 2025 has the potential to be transformational at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plus-therapeutics-reports-fourth-quarter-200500131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","PSTV","LENZ","BK4135","BK4139"],"gpt_icon":1},{"id":"2521283887","title":"Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521283887","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521283887?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:34","pubTimestamp":1742553296,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc.  stands against other micro-, small-cap firms that dominate Thursday’s gains.The stock market edged lower on Thursday, erasing gains from the previous trading day that was buoyed by the Federal Reserve’s decision to keep rates unchanged.The tech-heavy Nasdaq decreased by 0.33 percent, the S&P 500 declined by 0.22 percent, and the Dow Jones dipped by 0.03 percent.On Thursday, investors immediately booked profits following the lack of fresh catalysts to further boost buying appetite.However, 10 companies under the micro- to small-cap sectors noticeably defied market pessimism, having surged by double to triple digits. In this article, we have identified Thursday’s 10 best performers and detailed the reasons behind their gains.We classify micro-cap companies as those between $50 million and $300 million in market capitalization,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-plus-therapeutics-inc-pstv-103456554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2521495785","title":"Equity Markets Fall After Latest Unemployment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2521495785","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521495785?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 03:52","pubTimestamp":1742500351,"startTime":"0","endTime":"0","summary":"US benchmark equity indexes were on track to close lower Thursday following the weekly unemployment insurance data and a day after the Federal Reserve decided to keep interest rates unchanged.The Dow ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DDM","SH","TQQQ","ACN","DOG","UPRO",".IXIC","VOO","NVIW.SI","LU1861220033.SGD","OEF","UDOW","OEX","SDOW","USAW.SI","EQR","US30Y.BOND","QLD","QID","PSTV","SQQQ",".SPX","PSQ","LU0545039389.USD","US3Y.BOND","IVV","US6M.BOND","MNQmain","TSYW.SI","DRI","JBL","US10Y.BOND",".DJI","IE00BSNM7G36.USD","LU0323240290.USD","NQmain","DJX","US12M.BOND","US5Y.BOND","SPXU","USJW.SI","SPY","SSO","DXD","SDS","ESmain","US2Y.BOND","US7Y.BOND","SG9999014880.SGD"],"gpt_icon":1},{"id":"2521446719","title":"Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521446719","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521446719?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 01:52","pubTimestamp":1742493124,"startTime":"0","endTime":"0","summary":"Plus Therapeutics  shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.Price: 1.45, Change: +0.93, Percent Change: +182.78","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","PSTV","BK4139"],"gpt_icon":0},{"id":"2520466052","title":"BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2520466052","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520466052?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:56","pubTimestamp":1742486202,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli LillyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q318Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBL","LU2764262908.HKD","PRA","ACN","KKR","STZ","CNNE","LENZ","LU0068578508.USD","YRD","FIVE","NOVA","COTY","EPAM","PSTV","BECN","QXO","IE00B3M56506.USD","LU1023057109.AUD","LU2764263039.SGD","AKBA","SPRY","LU2360106947.USD","BK4077","SCVL","EYEN","BK4600","CVNA","CLDX","IE00B5949003.HKD","LU0823414478.USD","IE00B4R5TH58.HKD","LU0310799852.SGD","ZK","MCHP","ELEV","OPTN","BKKT","ASO","LLY","LU1023059063.AUD","RIVN","DRI","BGSF","VVPR","WINT","SAG","PII"],"gpt_icon":1},{"id":"2520131458","title":"Plus Therapeutics announces FDA conditionally accepted name REYOBIQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2520131458","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520131458?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:35","pubTimestamp":1742470507,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) announces the U.S. Food and Drug Administration, FDA, has conditionally accepted the Company’s new proprietary name, REYOB...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-announces-fda-conditionally-accepted-name-reyobiq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-announces-fda-conditionally-accepted-name-reyobiq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","PSTV"],"gpt_icon":0},{"id":"2520211902","title":"Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520211902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520211902?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:30","pubTimestamp":1742383800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA3B7Y9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSTV","BK4139"],"gpt_icon":0},{"id":"2519838655","title":"Plus Therapeutics Inc  expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519838655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519838655?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:02","pubTimestamp":1741964579,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc  expected to post a loss of39cents a share - Earnings Preview Plus Therapeutics Inc PSTV.OQ PSTV.O is expected to show a rise in quarterly revenue when it reports  results on Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX1KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV"],"gpt_icon":1},{"id":"2518726979","title":"D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2518726979","media":"ACCESS Newswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518726979?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 23:00","pubTimestamp":1741705200,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system  cancers, announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million.\"This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,\" said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. \"We remain focused on meeting key near term milestones and creating long-term value for our stockholders.\". Aggregate gross proceeds to the Company are expected to be approximately $15.0 million plus the benefit to the Company from the cancelation of the $3.2 million in principal amount of senior convertib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/d-boral-capital-served-exclusive-150000290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","QLD","NQmain","BK4139","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ","BK4588","MNQmain","BK4112","IE00B64PRP62.GBP","BK4135","PSTV","CNS","BK4585","NVIW.SI","QID","LU2210149790.SGD","USJW.SI","SQQQ",".IXIC","PSQ","TSYW.SI","LU2095319765.USD","LU2210150020.SGD","USAW.SI","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2518424714","title":"Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders’ Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2518424714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518424714?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 19:31","pubTimestamp":1741606307,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTV"],"gpt_icon":0},{"id":"2517245951","title":"PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2517245951","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517245951?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 23:58","pubTimestamp":1741363080,"startTime":"0","endTime":"0","summary":"Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation  to its lead radiotherapeutic candidate, rhenium  obisbemeda, for treating leptomeningeal metastases  in patients with lung cancer. The stock continued to gain another 51.4% in after-hours trading following the news announcement.The FDA grants ODD to support the development of medicines for rare disorders that affect fewer than 200,000 people in the United States. The ODD makes the sponsor eligible to receive seven years of market exclusivity following a potential approval and tax credit for qualified clinical studies, as well as exemptions from certain FDA application fees, including the Prescription Drug User Fee Act  charge of $4.3 million in 2025.LM is a rare cancer complication in which the primary cancer spreads to the cerebrospinal fluid and leptomeninges that cover the brain and spinal cord.In the past year, shares of Plus T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pstv-stock-skyrockets-fdas-orphan-155800501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AMLX","BK4139","BMRN","IE0002270589.USD","XNCR","IE00B7SZLL34.SGD","BK4007","BK4566","IE00B19Z3B42.SGD","IE00B19Z3581.USD","PSTV"],"gpt_icon":1},{"id":"2517317354","title":"Plus Therapeutics Inc  expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517317354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517317354?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 23:03","pubTimestamp":1741359784,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc  expected to post a loss of39cents a share - Earnings Preview Plus Therapeutics Inc PSTV.OQ PSTV.O is expected to show a rise in quarterly revenue when it reports  results on Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL5N3PQ1EP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV"],"gpt_icon":0},{"id":"2517436566","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2517436566","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517436566?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:16","pubTimestamp":1741357004,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed pre-bell Friday as the Health Care Select Sector SPDR Fund  was 0.4% lower and the iShares Biotechnology ETF  was recently up 0.3%.Walgreens Boots Alliance  shares were nearly 7% higher after the company said it signed a definitive agreement to be acquired by an entity affiliated with Sycamore Partners for up to $23.7 billion.Acadia Healthcare  shares were almost 6% lower after the company priced a debt offering to raise $550 million, $50 million more than originally planned.Plus Therapeutics  shares advanced by over 43% after the company said its experimental drug, rhenium obisbemeda, demonstrated a median overall survival of 11 months in an early-stage study, outperforming the standard of care of 8 months for recurrent glioblastoma, a type of brain tumor.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","BK4185","BK4139","BK4128","BK4581","LU0321505868.SGD","PSTV","XLV","WBA","WBA.AU","BK4588","LU0321505439.SGD","BK4585","ACHC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://plustherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1014},{"period":"1month","weight":0.4074},{"period":"3month","weight":0.3103},{"period":"6month","weight":-0.1784},{"period":"1year","weight":-0.1784},{"period":"ytd","weight":0.3217}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.652174,"avgChangeRate":0.086434},{"month":2,"riseRate":0.521739,"avgChangeRate":0.019388},{"month":3,"riseRate":0.391304,"avgChangeRate":-0.010519},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.017896},{"month":5,"riseRate":0.5,"avgChangeRate":0.404923},{"month":6,"riseRate":0.217391,"avgChangeRate":-0.089219},{"month":7,"riseRate":0.391304,"avgChangeRate":-0.020953},{"month":8,"riseRate":0.304348,"avgChangeRate":-0.041134},{"month":9,"riseRate":0.521739,"avgChangeRate":-0.053123},{"month":10,"riseRate":0.304348,"avgChangeRate":-0.05654},{"month":11,"riseRate":0.347826,"avgChangeRate":0.002696},{"month":12,"riseRate":0.391304,"avgChangeRate":-0.022353}],"exchange":"NASDAQ","name":"Plus Therapeutics, Inc.","nameEN":"Plus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Plus Therapeutics, Inc.(PSTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Plus Therapeutics, Inc.,PSTV,Plus Therapeutics, Inc.股票,Plus Therapeutics, Inc.股票老虎,Plus Therapeutics, Inc.股票老虎国际,Plus Therapeutics, Inc.行情,Plus Therapeutics, Inc.股票行情,Plus Therapeutics, Inc.股价,Plus Therapeutics, Inc.股市,Plus Therapeutics, Inc.股票价格,Plus Therapeutics, Inc.股票交易,Plus Therapeutics, Inc.股票购买,Plus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Plus Therapeutics, Inc.(PSTV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Plus Therapeutics, Inc.(PSTV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}